Impact of insufficient drug efficacy of antiparkinson agents on patient’s quality of life: a cross-sectional study

Table 2 Comparison of PDQ-8-Summary Index between patient groups with and without insufficient efficacy of medication

	Total		Patients with insufficient efficacy		Patients without insufficient efficacy		p value^a
	n	PDQ-8-SI	n	PDQ-8-SI	Number	PDQ-8-SI	p value^a
Total	2422	38.9 ± 20.7	1712	42.0 ± 20.1	625	30.0 ± 19.5	<0.0001
Hoehn &Yahr stages
Stage I	75	26.7 ± 19.2	29	35.6 ± 22.0	42	19.6 ± 14.5	0.0004
Stage II	194	32.6 ± 20.1	118	38.3 ± 20.6	71	24.3 ± 15.5	<0.0001
Stage III	907	36.8 ± 17.8	697	38.3 ± 17.5	180	31.0 ± 18.2	<0.0001
Stage IV	300	48.0 ± 19.2	251	48.2 ± 19.2	39	45.8 ± 20.0	0.4557
Stage V	77	65.5 ± 23.0	59	67.4 ± 21.5	12	51.3 ± 25.5	0.0246

Data excluding 208 patients without response on PDQ-8-Summary Index and 85 patients without response on experienced insufficient efficacy of medication. Data are expressed as numbers of patients, mean ± SD, or p values
^a:student t-test (comparison between the two groups)

ISSN: 1471-2377